TW202342538A - 結合her-3及her-2或egfr之雙特異性抗體 - Google Patents

結合her-3及her-2或egfr之雙特異性抗體 Download PDF

Info

Publication number
TW202342538A
TW202342538A TW112107660A TW112107660A TW202342538A TW 202342538 A TW202342538 A TW 202342538A TW 112107660 A TW112107660 A TW 112107660A TW 112107660 A TW112107660 A TW 112107660A TW 202342538 A TW202342538 A TW 202342538A
Authority
TW
Taiwan
Prior art keywords
seq
domain
cetuximab
fab
bispecific
Prior art date
Application number
TW112107660A
Other languages
English (en)
Chinese (zh)
Inventor
尤金 祖科維斯基
皮耶 伊曼紐爾 傑洛德
克里斯托 拉寶特勒
拉比亞 艾蜜利亞
堤爾瑞 查德斯
安德瑞 佩雷格林
Original Assignee
法商拜奧穆尼克斯製藥公司
法商英瑟姆公司
法國蒙彼利埃大學
法國蒙彼利埃癌症研究中心
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 法商拜奧穆尼克斯製藥公司, 法商英瑟姆公司, 法國蒙彼利埃大學, 法國蒙彼利埃癌症研究中心 filed Critical 法商拜奧穆尼克斯製藥公司
Publication of TW202342538A publication Critical patent/TW202342538A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW112107660A 2022-03-02 2023-03-02 結合her-3及her-2或egfr之雙特異性抗體 TW202342538A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22305242.4 2022-03-02
EP22305242 2022-03-02

Publications (1)

Publication Number Publication Date
TW202342538A true TW202342538A (zh) 2023-11-01

Family

ID=80930221

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112107660A TW202342538A (zh) 2022-03-02 2023-03-02 結合her-3及her-2或egfr之雙特異性抗體

Country Status (9)

Country Link
US (1) US20250282892A1 (enExample)
EP (1) EP4486774A1 (enExample)
JP (1) JP2025510539A (enExample)
KR (1) KR20240154641A (enExample)
CN (1) CN119451982A (enExample)
AU (1) AU2023228330A1 (enExample)
CA (1) CA3244947A1 (enExample)
TW (1) TW202342538A (enExample)
WO (1) WO2023166098A1 (enExample)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
EP2282769A4 (en) * 2008-04-29 2012-04-25 Abbott Lab DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
BR112013003257A2 (pt) 2010-08-10 2016-06-14 Glycotope Gmbh anticorpos egfr humanizados.
EP2543680A1 (en) 2011-07-07 2013-01-09 Centre National de la Recherche Scientifique Multispecific mutated antibody Fab fragments
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
JP5786839B2 (ja) 2012-12-05 2015-09-30 株式会社デンソー エポキシ樹脂組成物および接着構造体の製造方法
JP7014724B2 (ja) * 2016-02-06 2022-02-01 エピムアブ バイオセラピューティクス インコーポレイテッド タンデム型Ｆａｂ免疫グロブリンおよびその使用
WO2020136566A1 (en) 2018-12-24 2020-07-02 Sanofi Multispecific binding proteins with mutant fab domains

Also Published As

Publication number Publication date
KR20240154641A (ko) 2024-10-25
JP2025510539A (ja) 2025-04-15
EP4486774A1 (en) 2025-01-08
AU2023228330A1 (en) 2024-09-19
CA3244947A1 (en) 2023-09-07
US20250282892A1 (en) 2025-09-11
CN119451982A (zh) 2025-02-14
WO2023166098A1 (en) 2023-09-07

Similar Documents

Publication Publication Date Title
KR102360742B1 (ko) Egfr 및 her2 를 표적하는 이특이적 항체
US12528877B2 (en) Binding molecules to CD38 and PD-L1
CA2816519A1 (en) Pan-her antibody composition
KR20140138353A (ko) 단일특이적 및 이중특이적 항-igf-1r 및 항 erbb3 항체
US20250236682A1 (en) Antigen-binding protein comprising two fc domains and use thereof
US20250382386A1 (en) Anti-alk-1 antibody and use thereof
US20250282892A1 (en) Bispecific antibodies binding to her-3 and to either her-2 or egfr
JP2026511642A (ja) 抗ｌａｇ３抗体、医薬組成物及び用途
WO2025027511A1 (en) Molecules that bind to mutant calreticulin and uses thereof
HK40073118B (en) Binding molecules to cd38 and pd-l1
EA051954B1 (ru) Мультиспецифические антитела, которые связывают как mait, так и опухолевые клетки
HK40002344B (en) Binding molecules to cd38 and pd-l1